This inventor holds 7 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: Novartis Ag, University of Pennsylvania. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
7 out of 3,978 
7 out of 2,659 
Years Active: 2019-2025
Title: Na Li: Innovator in Chimeric Antigen Receptor Therapies
Introduction
Na Li is a prominent inventor based in Cambridge, MA (US), known for his significant contributions to the field of immunotherapy. He holds a total of seven patents, focusing primarily on innovative therapies targeting CD20 and CD22 antigens. His work has the potential to revolutionize treatments for diseases associated with these antigens.
Latest Patents
Na Li's latest patents include groundbreaking therapies such as CD20 therapies, CD22 therapies, and combination therapies utilizing a CD19 chimeric antigen receptor (CAR)-expressing cell. These inventions provide compositions and methods for treating diseases linked to CD19 expression. They involve administering a recombinant T cell that comprises the CD19 CAR, in conjunction with various B-cell inhibitors. Additionally, his patents feature novel antigen binding domains and CAR molecules directed at CD20 and CD22, which can be used as monotherapies or in combination therapies. The inventions also encompass kits and compositions that facilitate these treatments. Furthermore, he has developed nucleic acid molecules encoding chimeric antigen receptors that target CD20 or CD22, along with methods for administering genetically modified T cells or natural killer (NK) cells expressing these CARs.
Career Highlights
Throughout his career, Na Li has worked with esteemed organizations such as Novartis AG and the University of Pennsylvania. His experience in these institutions has significantly contributed to his expertise in the development of innovative therapies.
Collaborations
Na Li has collaborated with notable colleagues, including Jennifer Brogdon and Lu Huang. These partnerships have fostered a collaborative environment that enhances the development of cutting-edge therapies.
Conclusion
Na Li's contributions to the field of immunotherapy through his innovative patents and collaborations position him as a leading inventor in the treatment of diseases associated with CD20 and CD22. His work continues to pave the way for advancements in medical therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile